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Abstract
Objectives: To analyze the clinical and immunological characteristics at enrollment in a large prospective cohort of patients
with primary Sjo¨gren’s syndrome (pSS) and to investigate the association between serum BAFF, beta2-microglobulin and
free light chains of immunoglobulins and systemic disease activity at enrollment.
Methods: Three hundred and ninety five patients with pSS according to American-European Consensus Criteria were
included from fifteen centers of Rheumatology and Internal Medicine in the ‘‘Assessment of Systemic Signs and Evolution of
Sjo¨gren’s Syndrome’’ (ASSESS) 5-year prospective cohort. At enrollment, serum markers were assessed as well as activity of
the disease measured with the EULAR Sjo¨gren’s Syndrome Disease Activity Index (ESSDAI).
Results: Patient median age was 58 (25th–75th: 51–67) and median disease duration was 5 (2–9) years. Median ESSDAI at
enrollment was 2 (0–7) with 30.9% of patients having features of systemic involvement. Patients with elevated BAFF, beta2-
microglobulin and kappa, lambda FLCS had higher ESSDAI scores at enrollment (4 [2–11] vs 2 [0–7], P= 0.03; 4 [1–11] vs 2
[0–7], P, 0.0001); 4 [2–10] vs 2 [0–6.6], P, 0.0001 and 4 [2–8.2] vs 2 [0–7.0], P= 0.02, respectively). In multivariate analysis,
increased beta2-microglobulin, kappa and lambda FLCs were associated with a higher ESSDAI score. Median BAFF and
beta2-microglobulin were higher in the 16 patients with history of lymphoma (1173.3(873.1–3665.5) vs 898.9 (715.9–1187.2)
pg/ml, P= 0.01 and 2.6 (2.2–2.9) vs 2.1 (1.8–2.6) mg/l, P= 0.04, respectively).
Conclusion: In pSS, higher levels of beta2-microglobulin and free light chains of immunoglobulins are associated with
increased systemic disease activity.
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Introduction
In autoimmune diseases, using biomarkers to allow the
identification of patients at risk of flares or complications remains
an unmet need. These patients would thus benefit from a
tightened follow-up and earlier use of immunosuppressant agents
to limit end-organ damage and mortality.
Patients with primary Sjo¨gren’s syndrome (pSS), the most
common systemic autoimmune disease after rheumatoid arthritis,
would particularly benefit from the identification of disease activity
and prognostic markers. The hallmarks of pSS involve a disabling
dry syndrome associated with asthenia and pain, but the course of
the disease cannot be predicted and one third of the patients will
develop systemic manifestations [1,2]. Moreover, 5% to 10% of
patients will develop lymphoma [3–5], and only few predictive
factors of this severe complication have been identified to date.
Lastly, conversely to many other autoimmune diseases, the use of
acute phase reactants is limited because elevation of C-reactive
protein is rare and the elevation of the erythrocyte sedimentation
rate is frequently due to hypergammaglobulinemia.
A very important milestone to allow the identification of
biomarkers was accomplished by the establishment of an
international consensus disease activity score, named the ESSDAI
(EULAR Sjo¨gren’s Syndrome Disease Activity Index) [6]. This
quantitative score includes 12 domains corresponding to various
clinical and biological features. The nature of each of these
involvements was consensually defined. The pathogenesis of pSS
involves both genetic and environmental factors, which trigger
innate and adaptive immunity, including T and B lymphocytes (2).
Concordant data from several groups have emphasized the role of
type-I interferon-inducible proteins, including BAFF (B-cell
Activation of the TNF Family, also named BLyS) in the activation
of B lymphocytes [7]. Elevated BAFF has been evidenced in the
serum and target organs of pSS (salivary glands, conjunctival
epithelial cells of the ocular surface). BAFF is secreted not only by
monocytes and dendritic cells but also by T and B lymphocytes
and salivary gland epithelial cells in pSS [8–11]. B lymphocytes in
pSS have a decreased BAFF-R expression, possibly related to
BAFF overexpression and this is more marked in patients with
systemic features [12]. Lymphoma is thought to result from
persistent activation of B-cells, to which the increased BAFF
concentration might contribute [13]. Previous studies have
suggested that the activation of B-cells could contribute to systemic
complications in pSS [14–19] but they were retrospective or cross-
sectional, concerned one isolated serum marker (beta2-micro-
globulin [18] or BAFF [19] for example), past or current systemic
complications, without concomitant assessment of disease activity
and serum markers. Last, until the recent establishment of the
ESSDAI, disease activity was almost exclusively defined by the
presence or absence of systemic manifestations.
We have therefore set up a multicenter 5-year prospective
cohort and associated biobank named ASSESS (Assessment of
Systemic Signs and Evolution in Sjo¨gren’s Syndrome) in France in
order to determine whether serum BAFF, beta2-microglobulin,
free light chains of immunoglobulins (primary objective) or other
serum or mRNA markers (secondary objectives) could predict the
occurrence of systemic complications including lymphoma.
Since the patients have not achieved their expected 5 years of
follow-up, the objectives of the present study are to describe the
baseline characteristics of the ASSESS cohort and to investigate
the association of serum BAFF, beta2-microglobulin, kappa and
lambda free light chains of immunoglobulins (FLCs) with systemic
disease activity scored by the ESSDAI, concomitantly evaluated at
inclusion in the prospective ASSESS cohort.
Patients and Methods
Patients
The ASSESS national multi-center prospective cohort (Assess-
ment of Systemic Signs and Evolution in Sjo¨gren’s Syndrome) was
set up in 2006 with a grant of the French Ministry of Health
(Programme Hospitalier de Recherche Clinique 2005 P060228).
Its primary objective was to identify valuable predictive factors of
systemic complications and lymphoma in pSS during a 5-year
prospective follow-up.
The study, promoted by the Assistance Publique des Hoˆpitaux
de Paris, was approved by the Ethics Committee of Hoˆpital Bichat
and the ‘‘Commission Nationale Informatique et Liberte´s’’ in
2006. All patients gave their informed written consent.
Four hundred and ten patients with pSS fulfilling American-
European Consensus Criteria (AECG) were consecutively includ-
ed from fifteen tertiary centers for autoimmune diseases between
2006 and 2009.
The present and previous systemic complications including skin,
articular, lung, kidney, peripheral and central nervous system,
muscular involvement and vasculitis, as well as lymphoma, were
recorded. The diagnosis and the histological subtypes of previous
lymphomas were confirmed by reanalysis of the medical and
histological records by one of us (XM).
A thoroughly standardized paper clinical report form (CRF) was
prospectively completed by participating clinicians each year for a
total of 5 years. Disease systemic activity was assessed by the
ESSDAI. This quantitative score (range: 0 to 123) has 12 domains
[6]. For instance, pSS-related articular involvement as defined by
the articular domain of the ESSDAI corresponds to arthralgias in
hands, wrists, ankles and feet accompanied by morning stiffness
(.30 min) and/or synovitis. The biological domain corresponds to
the presence of hypocomplementemia, clonal component, cryo-
globulinemia, hypergammaglobulinemia or high IgG level, recent
onset hypogammaglobulinemia or recent decrease of IgG level
(,5 g/L). The haematological domain corresponds to the
presence of a cytopenia of auto-immune origin (neutropenia,
anemia, thrombocytopenia, or lymphopenia [6].
The ESSPRI score (EULAR Sjo¨gren’s Syndrome Patient
Related Index), a patient reported outcome multinational consen-
sus score evaluating dryness, fatigue, and pain, was completed by
all patients each year [20]. Dryness was objectively assessed at
enrollment and after 2 and 5 years of follow-up using unstimulated
salivary flow (USF) and Schirmer’s test. After monitoring, data
were included in an electronic database.
Assessment of serum markers
DNA, blood RNA and serum samples were obtained at
enrollment. All biological samples were immediately frozen, stored
and shipped to the Centre de Ressources Biologiques of Bichat
Hospital, which has obtained the French Association for Quality
Insurance (AFAQ) (certification number 2009/34457) according
to the norm 96900. Blood RNA was collected using a Paxgene
tube, extracted using a Qiagen extraction kit, and stored at
280uC. The NanoDrop ND-1000 UV-Vis spectrophotometer was
used to determine the quantity and the purity of DNA that have
been isolated. Agilent’s 2100 Bioanalyzer was used to determine
both RNA concentration and integrity showing two distinct
ribosomal peaks corresponding to either to 18S and 28S. The
28S/18S calculated ratio was used to serve as an indication of
RNA integrity. Serum markers were assessed centrally and blindly
from any clinical or other biological data. Rheumatoid factor (RF)
was assessed using Enzyme-Linked Immunosorbent Assay
(ELISA), C3 and C4 using nephelometry (decreased C3 and C4
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defined as a value below 0.8 and 0.15 g/l, respectively). Beta2-
microglobulin, total Ig levels, kappa and lambda FLCs of Igs were
assessed by nephelometry using the Freelite kit (Binding Site),
BAFF was measured using ELISA (Quantikine kit, R&D Systems).
Increased concentrations of beta2-microglobulin, kappa and
lambda free light chains, or abnormal kappa to lambda ratio
were defined according to the manufacturer (greater than 2.3 mg/
l, 19.4 mg/l, 26.3 mg/l, and less than 0.26 or over 1.65,
respectively). Serum elevated BAFF was defined by a value greater
or equal to the mean (916.96271.2 pg/ml )+2 standard deviations
(1459.3 pg/ml) of 80 age and sex-matched control subjects
(subjects with dry symptoms but without any autoantibody and
without lymphocytic infiltrates on minor salivary gland biopsy).
CD4 and CD8 T cell counts were determined using flow
cytometry. CD4+ T lymphocytopenia was defined by an absolute
CD4 count lower than 300 cells/ml [21].
Table 1. Characteristics of patients at enrollment in the
ASSESS cohort.
Median age (years) 58 (51–67)
Male/female 93.6/6.4%
Disease duration (years) 5 (2–9)
Decreased salivary flow at enrollment 162/327 (47.5%)
Focus score $ 1 318/352 (87.8%)
Previous systemic involvement 34.1%
Previous lymphoma 4.7%
Active current systemic involvement 30.9%
No active nor previous involvement 28.8%
Enlarged parotids at enrollment 11.4%
Purpura at enrollment 2.3%
ESSDAI 2.0 (0.–7.0)
ESSPRI 5.7 (4.0–7.0)
Treatment with corticosteroids at enrollment 23.7%
Median dosage 5 mg/day
Treatment with hydroxychloroquine
at enrollment
30.7%
Treatment with other immunosuppressants at enrollment
MTX 5.1%
LEF 0.5%
AZA 1.5%
MMF 1.3%
RTX in the 6 months preceding enrollment 1%
Anti-SSA positive antibodies 59.2%
Anti-SSB positive antibodies 33.5%
RF-positive 153/372 (41.1%)
Cryoglobulinemia 57/335 (17.0%)
Low C4 (, 0.15 g/l) 72/371 (19.4%)
IgG, g/l; high IgG (.16 g/l) 12.5 (9.9–16.8); 29.3%
Serum monoclonal immunoglobulin 13.1%
CD4+ T cell lymphocytopenia (,300 cells/ml ) 9.8%
CD4/CD8 , 0.8 19/338 (5.6%)
BAFF (pg/ml) 909.0 (719.1–1196.1)
Beta2-microglobulin (mg/l) 2.2 (1.8–2.6)
Elevated levels, % 38.4%
Immunoglobulin kappa free light chains (mg/l) 13.5 (10.1–19.2)
Elevated levels, % 24.4%
Lambda free light chains (mg/l) 13.2 (9.8–18.8)
Elevated levels, % 10.1
Abnormal kappa to lambda ratio, % 7.4
Results are expressed as medians (25th–75th percentiles) unless otherwise
specified. MTX: methotrexate; LEF: leflunomide; AZA: azathioprine; MMF:
mycophenolate mofetil; RTX: rituximab; RF: rheumatoid factor.
doi:10.1371/journal.pone.0059868.t001
Table 2. Patients with active disease in the various ESSDAI
domains at enrollment.
Domain
Proportion of patients with
disease activity
Skin 4.2%
Pulmonary 14.4%
Renal 2.8%
Articular 18.6%
Muscular 3.3%
Peripheral neuropathy 9.6%
Central nervous system 2.0%
Glandular 12.1%
Constitutional 4.1%
Haematological 15.6%
Lymphadenopathy 2.4%
Biological 37.4%
Clinical involvement corresponding to each of these twelve domains is defined
according to the ESSDAI (ref 6).
doi:10.1371/journal.pone.0059868.t002
Table 3. Association between autoantibodies, serum markers
and ESSDAI.
ESSDAI
P value,
univariate
P value,
multivariate
Anti-SSA + 3 (1–8) 0.02 0.6
Anti-SSA 2 2 (0–6)
RF + 3 (1–8) 0.2 0.2
RF 2 2 (0–7)
Elevated BAFF 4 (2–11) 0.03 0.1
Normal BAFF 2 (0–7)
Elevated b2 4 (1–11) ,1024 0.03
Normal b2 2 (0–7)
Elevated k 4 (2–10) ,1024 0.02
Normal k 2 (0–6.6)
Elevated l 4 (2–8.2) 0.02 0.5
Normal l 2 (0–7.0)
aSSA +: anti-SSA-positive(anti-SSA alone or anti-SSA plus anti-SSB); RF:
rheumatoid factor; b2: beta2-microglobulin; k: kappa free light chains of
immunoglobulins; l: lambda free light chains of immunoglobulins.
Results are expressed as medians (25th–75th).
doi:10.1371/journal.pone.0059868.t003
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Statistical analysis
Continuous data are presented as medians with interquartile
ranges. We used nonparametric tests to analyze continuous
variables, despite the large number of patients, because the
distribution of data was uneven. The Mann-Whitney U test was
used to compare continuous data and the chi-squared test to
compare nominal data. Correlations were studied with Spear-
man’s rank test. Biological markers associated with the ESSDAI by
univariate analysis were included in multivariate linear and logistic
regression models. All statistical analyses were performed with
Stata SE 9.2 (Stata Corporation, College Station, TX, USA).
Results
Characteristics of patients and serum levels of BAFF,
beta2-microgobulin and immunoglobulin free light
chains
410 patients were included in the cohort. Fifteen patients were
excluded from the cohort since they did not fulfill the AECG
criteria for pSS (n= 14) or withdrew consent (n = 1). The
characteristics of the 395 patients with pSS are summarized in
Table 1. 93.6% of patients were women, median age was 58 (51–
67) years and median disease duration was 5 (2–9) years. 59.2% of
patients were anti-SSA positive and 33.5% anti-SSB positive.
41.1% of patients were rheumatoid factor-positive. 34.1% of the
patients had a history of systemic involvement. 30.9% of patients
had active systemic involvement at enrollment. The median
ESSDAI score was 2 (0–7.0). At enrollment, 23.7% were treated
with corticosteroids (median dosage 5 mg/day), 30.7% with
hydroxychloroquine (HQ), 9.4% with an immunosuppressant
other than HQ or corticosteroids (Table 1). Median levels of
BAFF, beta2- microglobulin and free light chains of immunoglob-
ulin levels are reported in Table 1.
For all the further analyses on markers of B-cell activation, two
patients were excluded since they had been prescribed rituximab
within 12 months before enrollment in the cohort, a treatment
which might especially affect serum BAFF levels [22,23]. Patients
with anti-SSA or with both anti-SSA and anti-SSB autoantibodies
had significantly higher levels of BAFF, beta2-microgobulin and
immunoglobulin free light chains (data not shown). Serum BAFF
level was weakly but significantly correlated with serum beta2-
microglobulin (r = 0.2, P,0.0001), but not with IgG, kappa and
lambda immunoglobulin free light chains or RF concentrations
(data not shown).
Association between the systemic disease activity at
enrollment in the ASSESS cohort and serum levels of
BAFF, beta2-microgobulin and immunoglobulin free
light chains
The median ESSDAI was 2 (0–7.0). The proportion of patients
who, at enrollment, had active disease, defined by the presence of
at least low, or moderate or high disease activity in the various
domains of the ESSDAI [6], is indicated in Table 2. Patients with
anti-SSA/SSB, or increased markers of BAFF, beta2-microglobu-
lin, immunoglobulin kappa and lambda free lights chains had a
significantly higher ESSDAI. Multivariate linear regression
analysis indicated that only beta2-microglobulin and kappa FLC
concentrations were associated with the ESSDAI (Table 3).
Conversely, the ESSPRI, which evaluates patient’s dryness,
fatigue, and pain, was not associated with increases in BAFF,
beta2-microglobulin, kappa and lambda FLCs. These serum
markers were not increased either in patients with decreased
unstimulated salivary flow or abnormal Schirmer’s test (data not
shown).
Increased serum BAFF and beta2-microglobulin in
patients with a history of lymphoma
The cohort included 16 patients with a history of lymphoma,
without any rituximab treatment in the past 12 months, 10 of
whom had been treated with rituximab more than 1 year ago. The
median time between the diagnosis of lymphoma and enrollment
in the cohort was 6 years (0–11). Baseline serum BAFF and beta2-
microglobulin were significantly higher in these 16 patients with
history of lymphoma than in the others (1173.3 (873.1–3665.5) vs
898.9 pg/ml (715.9–1187.2), P=0.01 and 2.6 (2.2–2.9) vs 2.1
(1.8–2.6) mg/, P=0.04, respectively). A history of lymphoma was
not associated with serum FLCs, an abnormal kappa to lambda
ratio or the RF concentration (data not shown). After exclusion of
the 3 patients not in remission of lymphoma, the disease activity at
enrollment (ESSDAI: 4.0 (1.2–8.6)) of the 13 patients with a
history of lymphoma and in remission was not significantly higher
than that of the other patients (2.0 (0–6.8), P=0.5). Regarding the
3 main biological factors associated with a risk of lymphoma [24–
26], a low C4 and a CD4/CD8 ratio lower than 0.8, were
significantly more frequent in patients with a history of lymphoma
and there was a trend towards an association with cryoglobulin-
emia (Table 4).
Discussion
The present study reports the clinical and immunological
characteristics of patients with pSS at enrollment in a large
Table 4. Characteristics associated with a history of lymphoma.
Patient with history of lymphoma (n=16)
Patients without history of lymphoma
(n=377) P value
BAFF, pg/ml 1173.3(873.1–3665.5) 898.9 (715.9–1187.2) 0.01
Beta2- microglobulin, mg/l 2.6 (2.2–2.9) 2.1 (1.8–2.6) 0.04
Cryoglobulinemia 35.7% 16.7% 0.2
Low C4 (, 0.15 g/l) 57.1% 17.9% 0.003
CD4+T lymphocytopenia (,300 cells/ml) 28.5% 8.7% 0.06
CD4/CD8 ratio,0.8 28.5% 4.8% 0.01
Results are expressed as medians (25th–75th percentiles) unless otherwise specified.
doi:10.1371/journal.pone.0059868.t004
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prospective cohort and demonstrates the association between
systemic disease activity assessed by the ESSDAI and beta2-
microglobulin and free light chains of immunoglobulins.
First, this study reports the characteristics of patients at
enrollment in a large multicenter 5-year prospective cohort. A
better knowledge of the clinical outcome, the course of disease
activity and the risk factors of lymphoma in pSS require the setting
up of cohorts with biobanks [27]. Three large prospective cohorts,
including the present one, have already started to enroll patients
with pSS. The clinical manifestations and immunological patterns
in the ASSESS cohort are representative of the patients with pSS
referred to rheumatology or internal medicine centers. In addition,
only a limited proportion of the patients were treated with low
doses of corticosteroids, or immunosuppressants other than
hydroxychloroquine. Thus, the analysis of serum markers was
not flawed by the use of immunosuppressants. The storage of all
samples in a biological resource center and the central processing
and analysis, blinded from the clinical data, ensures the quality of
the stored sera and resulting data. Last, this is the first large cohort
in which ESSDAI scores of clinical activity and different serum
biomarkers have been evaluated simultaneously.
However, this study has some limitations. It is currently a cross-
sectional study and it is necessary to wait for years before being
able to evaluate the interest of these biomarkers as predictive
factors of complications. In addition, among the 12 domains of the
ESSDAI score, there is one biological domain which takes into
account different parameters than those assessed in this study:
levels of gammaglobulins, IgG and complement, and presence of
monoclonal component and cryoglobulinemia. However, remov-
ing this domain from the ESSDAI represents a methodological
nonsense since the ESSDAI has been built with all these 12
domains with a specific weight calculated for each of them. Thus,
it was not possible to compare the value as disease activity markers
of BAFF, beta2-microglobulin and free light chains of immuno-
globulins with that of the biological domain (gammaglobulins, Ig
or complement).
There is clearly a rationale to investigate serum BAFF, beta2-
microglobulin and free light chains of immunoglobulins as disease
activity markers in pSS. Retrospective studies have shown that
beta2-microglobulin and free light chains levels are associated with
extra-glandular complications [14–18]. Recently, 2 retrospective
studies including 78 and 76 pSS patients showed in univariate
analysis a significant correlation between the ESSDAI and serum
beta2-microglobulin and BAFF, respectively [18,19]. This study
extends these findings by analyzing in a multivariate manner, in a
large cohort, the relative contribution of both markers with
regards to anti-SSA/SSB, RF, and free light chains of immuno-
globulins. Patients with increases in BAFF, beta2-microglobulin or
free light chains of immunoglobulins, had an approximately two-
fold increase in their ESSDAI value. No such an association was
observed with autoantibodies, since RF was not associated in
univariate analysis and anti-SSA/SSB antibodies were not
associated in multivariate analysis with the ESSDAI. In addition,
positivity for anti-SSA/SSB is genetically determined [28] and a
previous study showed that their quantitative levels were not
associated with extraglandular involvement [29]. Of note, there
was no association between the studied serum markers and
unstimulated salivary flow or Schirmer’s test or with the new
international consensus patient-related outcome score, the ES-
SPRI, which evaluates patient’s pain, fatigue and symptoms of
dryness.
The primary objective of this prospective cohort is to identify
factors predicting the occurrence of systemic complications and
especially of lymphoma. It was recently demonstrated in a
retrospective study that patients with pSS and lymphoma had
higher levels of BAFF at the time of diagnosis of lymphoma [19].
Interestingly, patients with a history of lymphoma included in
ASSESS cohort had elevated serum concentrations of BAFF and
beta2-microglobulin. Elevated BAFF and beta2-microglobulin
concentrations in patients with history of lymphoma were not
due to greater systemic disease activity at enrollment. Elevated
serum BAFF and beta2-microglobulin are associated with a poor
prognosis in non-Hodgkin lymphomas that occur independently
from autoimmunity [13]. But 13 out of our 16 patients with a
history of lymphoma had been in remission for 6 years before
enrollment and still had elevated serum BAFF and beta2-
microglobulin concentrations at inclusion in the cohort. This
might suggest a genetic origin of such a persistent increase in
BAFF level. The –871 CRT single nucleotide gene polymorphism
(SNP) has not been associated with pSS but with the serum BAFF
concentration in patients with pSS [30,31], with mixed cryoglob-
ulinemia [32], with familial chronic lymphoproliferations [33,34],
and in patients with idiopathic thrombopenic purpura [35].
However, the study of a haplotype block including four SNPs
(22841 TRC, 22704 TRC, 22701 TRA, 2871 CRT),
suggested that the 2871 T allele was unlikely to be a sole, major
determinant of serum BAFF levels [31]. It is now necessary to
assess the relevance of serum BAFF and beta2-microglobulin
concentrations as markers predicting new cases of lymphoma
during the 5-year prospective follow-up of the ASSESS cohort.
Conclusion
The association of serum beta2-microglobulin and free light
chains of immunoglobulins with systemic disease activity offers
clinical perspectives to personalize healthcare in pSS. Should these
biomarkers be validated in the prospective ASSESS cohort, they
could help to identify pSS patients at risk of systemic complications
who need closer clinical monitoring and facilitate the selection of
patients who may benefit from more aggressive immunosuppres-
sive therapy to avoid these complications.
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